Biomarin Pharmaceutical
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $745,740 | $708,658 | $648,833 | $646,207 |
Gross Profit | 557,283 | 563,900 | 509,355 | 510,729 |
EBITDA | 156,415 | 162,173 | 136,444 | 52,286 |
EBIT | 137,409 | 135,710 | 109,094 | 25,425 |
Net Income | 106,080 | 107,174 | 88,662 | 20,375 |
Net Change In Cash | 745,740 | 708,658 | 648,833 | 646,207 |
Free Cash Flow | 200,305 | 96,923 | 12,867 | -9,213 |
Cash | 675,448 | 972,150 | 746,996 | 755,127 |
Basic Shares | 197,147 | 200,505 | 199,262 | 191,838 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $2,419,226 | $2,096,039 | $1,846,275 | $1,860,455 |
Gross Profit | 1,842,161 | 1,612,370 | 1,375,760 | 1,336,183 |
EBITDA | 310,284 | 267,515 | 48,026 | -5,850 |
EBIT | 205,898 | 165,546 | -60,013 | -111,727 |
Net Income | 167,645 | 141,561 | -64,080 | 854,029 |
Net Change In Cash | 2,419,226 | 2,096,039 | 1,846,275 | 1,860,455 |
Cost of Revenue | -61,882 | 211,712 | ||
Free Cash Flow | 51,648 | 44,362 | 185,311 | -52,154 |
Cash | 755,127 | 724,531 | 587,276 | 649,158 |
Basic Shares | 191,595 | 188,963 | 182,852 | 191,678 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | $0.55 |
2024-06-30 | $0.56 |
2024-03-31 | $0.46 |
2023-12-31 | $0.18 |
